Cargando…

Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare, aggressive brain neoplasm that accounts for roughly 2-6% of primary brain tumors. In contrast, glioblastoma (GBM) is the most frequent and severe glioma subtype, accounting for approximately 50% of diffuse gliomas. The aim of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Malikova, H., Koubska, E., Weichet, J., Klener, J., Rulseh, A., Liscak, R., Vojtech, Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126849/
https://www.ncbi.nlm.nih.gov/pubmed/27894359
http://dx.doi.org/10.1186/s40644-016-0098-9
_version_ 1782470181942984704
author Malikova, H.
Koubska, E.
Weichet, J.
Klener, J.
Rulseh, A.
Liscak, R.
Vojtech, Z.
author_facet Malikova, H.
Koubska, E.
Weichet, J.
Klener, J.
Rulseh, A.
Liscak, R.
Vojtech, Z.
author_sort Malikova, H.
collection PubMed
description BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare, aggressive brain neoplasm that accounts for roughly 2-6% of primary brain tumors. In contrast, glioblastoma (GBM) is the most frequent and severe glioma subtype, accounting for approximately 50% of diffuse gliomas. The aim of the present study was to evaluate morphological MRI characteristics in histologically-proven PCNSL and GBM at the time of their initial presentation. METHODS: We retrospectively evaluated standard diagnostic MRI examinations in 54 immunocompetent patients (26 female, 28 male; age 62.6 ± 11.5 years) with histologically-proven PCNSL and 54 GBM subjects (21 female, 33 male; age 59 ± 14 years). RESULTS: Several significant differences between both infiltrative brain tumors were found. PCNSL lesions enhanced homogenously in 64.8% of cases, while nonhomogeneous enhancement was observed in 98.1% of GBM cases. Necrosis was present in 88.9% of GBM lesions and only 5.6% of PCNSL lesions. PCNSL presented as multiple lesions in 51.9% cases and in 35.2% of GBM cases; however, diffuse infiltrative type of brain involvement was observed only in PCNSL (24.1%). Optic pathways were infiltrated more commonly in PCNSL than in GBM (42.6% vs. 5.6%, respectively, p <0.001). Other cranial nerves were affected in 5.6% of PCNSL, and in none of GBM. Signs of bleeding were rare in PCNSL (5.6%) and common in GBM (44.4%); p < 0.001. Both supratentorial and infratentorial localization was present only in PCNSL (27.7%). Involvement of the basal ganglia was more common in PCNSL (55.6%) than in GBM (18.5%); (p < 0.001). Cerebral cortex was affected significantly more often in GBM (83.3%) than in PCNSL (51.9%); mostly by both enhancing and non-enhancing infiltration. CONCLUSION: Routine morphological MRI is capable of differentiating between GBM and PCNSL lesions in many cases at time of initial presentation. A solitary infiltrative supratentorial lesion with nonhomogeneous enhancement and necrosis was typical for GBM. PCNSL presented with multiple lesions that enhanced homogenously or as diffuse infiltrative type of brain involvement, often with basal ganglia and optic pathways affection.
format Online
Article
Text
id pubmed-5126849
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51268492016-12-08 Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma? Malikova, H. Koubska, E. Weichet, J. Klener, J. Rulseh, A. Liscak, R. Vojtech, Z. Cancer Imaging Research Article BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a rare, aggressive brain neoplasm that accounts for roughly 2-6% of primary brain tumors. In contrast, glioblastoma (GBM) is the most frequent and severe glioma subtype, accounting for approximately 50% of diffuse gliomas. The aim of the present study was to evaluate morphological MRI characteristics in histologically-proven PCNSL and GBM at the time of their initial presentation. METHODS: We retrospectively evaluated standard diagnostic MRI examinations in 54 immunocompetent patients (26 female, 28 male; age 62.6 ± 11.5 years) with histologically-proven PCNSL and 54 GBM subjects (21 female, 33 male; age 59 ± 14 years). RESULTS: Several significant differences between both infiltrative brain tumors were found. PCNSL lesions enhanced homogenously in 64.8% of cases, while nonhomogeneous enhancement was observed in 98.1% of GBM cases. Necrosis was present in 88.9% of GBM lesions and only 5.6% of PCNSL lesions. PCNSL presented as multiple lesions in 51.9% cases and in 35.2% of GBM cases; however, diffuse infiltrative type of brain involvement was observed only in PCNSL (24.1%). Optic pathways were infiltrated more commonly in PCNSL than in GBM (42.6% vs. 5.6%, respectively, p <0.001). Other cranial nerves were affected in 5.6% of PCNSL, and in none of GBM. Signs of bleeding were rare in PCNSL (5.6%) and common in GBM (44.4%); p < 0.001. Both supratentorial and infratentorial localization was present only in PCNSL (27.7%). Involvement of the basal ganglia was more common in PCNSL (55.6%) than in GBM (18.5%); (p < 0.001). Cerebral cortex was affected significantly more often in GBM (83.3%) than in PCNSL (51.9%); mostly by both enhancing and non-enhancing infiltration. CONCLUSION: Routine morphological MRI is capable of differentiating between GBM and PCNSL lesions in many cases at time of initial presentation. A solitary infiltrative supratentorial lesion with nonhomogeneous enhancement and necrosis was typical for GBM. PCNSL presented with multiple lesions that enhanced homogenously or as diffuse infiltrative type of brain involvement, often with basal ganglia and optic pathways affection. BioMed Central 2016-11-29 /pmc/articles/PMC5126849/ /pubmed/27894359 http://dx.doi.org/10.1186/s40644-016-0098-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Malikova, H.
Koubska, E.
Weichet, J.
Klener, J.
Rulseh, A.
Liscak, R.
Vojtech, Z.
Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
title Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
title_full Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
title_fullStr Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
title_full_unstemmed Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
title_short Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
title_sort can morphological mri differentiate between primary central nervous system lymphoma and glioblastoma?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126849/
https://www.ncbi.nlm.nih.gov/pubmed/27894359
http://dx.doi.org/10.1186/s40644-016-0098-9
work_keys_str_mv AT malikovah canmorphologicalmridifferentiatebetweenprimarycentralnervoussystemlymphomaandglioblastoma
AT koubskae canmorphologicalmridifferentiatebetweenprimarycentralnervoussystemlymphomaandglioblastoma
AT weichetj canmorphologicalmridifferentiatebetweenprimarycentralnervoussystemlymphomaandglioblastoma
AT klenerj canmorphologicalmridifferentiatebetweenprimarycentralnervoussystemlymphomaandglioblastoma
AT rulseha canmorphologicalmridifferentiatebetweenprimarycentralnervoussystemlymphomaandglioblastoma
AT liscakr canmorphologicalmridifferentiatebetweenprimarycentralnervoussystemlymphomaandglioblastoma
AT vojtechz canmorphologicalmridifferentiatebetweenprimarycentralnervoussystemlymphomaandglioblastoma